BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04021043 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 16, 2019
Last Update Posted : February 16, 2023
|
Sponsor:
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This phase I/II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and nivolumab with or without stereotactic body radiation therapy and to see how well they work in treating patients with lung/chest or liver cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as BMS-986156, ipilimumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. It is not yet known whether giving BMS-986156, ipilimumab, and nivolumab with or without stereotactic body radiation therapy will work better in treating patients with lung/chest or liver cancers.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced Malignant Solid Neoplasm Metastatic Carcinoma in the Liver Metastatic Carcinoma in the Lung Metastatic Malignant Neoplasm in the Thoracic Cavity Metastatic Malignant Solid Neoplasm | Drug: Anti-GITR Agonistic Monoclonal Antibody BMS-986156 Biological: Ipilimumab Biological: Nivolumab Radiation: Stereotactic Body Radiation Therapy | Phase 1 Phase 2 |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 68 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies |
| Actual Study Start Date : | August 19, 2019 |
| Estimated Primary Completion Date : | August 29, 2023 |
| Estimated Study Completion Date : | August 29, 2023 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Group I (ipilimumab, BMS-986156, nivolumab)
Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 5 (day 85), patients receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
|
Drug: Anti-GITR Agonistic Monoclonal Antibody BMS-986156
Given IV
Other Names:
Biological: Ipilimumab Given IV
Other Names:
Biological: Nivolumab Given IV
Other Names:
|
|
Experimental: Group II (ipilimumab, BMS-986156, SBRT, nivolumab)
Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 2, patients then undergo SBRT on days 29-32 for 4 fractions or on days 29-40 for 10 fractions. Beginning day 1 of cycle 5 (day 85), patents receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
|
Drug: Anti-GITR Agonistic Monoclonal Antibody BMS-986156
Given IV
Other Names:
Biological: Ipilimumab Given IV
Other Names:
Biological: Nivolumab Given IV
Other Names:
Radiation: Stereotactic Body Radiation Therapy Undergo SBRT
Other Names:
|
|
Experimental: Group III (nivolumab, BMS-986156, SBRT)
Patients receive nivolumab IV over 30 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 over 60 minutes on day 1. Patients also undergo SBRT over 30-45 minutes on days 1-4 for 4 fractions or on days 1-12 for 10 fractions. Treatment repeats every 28 days for up to 26 cycles of nivolumab and for up to 4 cycles of anti-GITR agonistic monoclonal antibody BMS-986156 in the absence of disease progression or unacceptable toxicity.
|
Drug: Anti-GITR Agonistic Monoclonal Antibody BMS-986156
Given IV
Other Names:
Biological: Nivolumab Given IV
Other Names:
Radiation: Stereotactic Body Radiation Therapy Undergo SBRT
Other Names:
|
Primary Outcome Measures :
- Incidence of dose-limiting toxicities (DLT) [ Time Frame: Up to 29 days for groups 1 and 3, up to day 43 for group 2 ]Descriptive statistics will be computed.
- Incidence of adverse events of ipilimumab with anti-GITR agonistic monoclonal antibody BMS-986156 (BMS-986156) and stereotactic body radiation therapy (SBRT) targeting liver lesions [ Time Frame: Up to 1 year ]Will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Descriptive statistics will be computed. Safety will be compared in two separate analyses among different treatment regimens: treatment group 1 versus (vs.) treatment group 2, treatment group 2 vs. treatment group 3, and among different SBRT targets liver vs lung: treatment group 2 vs. treatment group 3.
- Incidence of adverse events of ipilimumab with BMS-986156 and SBRT targeting lung lesions [ Time Frame: Up to 1 year ]Will be assessed using CTCAE version 4.0. Descriptive statistics will be computed. Safety will be compared in two separate analyses among different treatment regimens: treatment group 1 vs. treatment group 2, treatment group 2 vs. treatment group 3, and among different SBRT targets liver vs lung: treatment group 2 vs. treatment group 3.
- Incidence of adverse events of nivolumab with BMS-986156 and SBRT targeting liver lesions [ Time Frame: Up to 1 year ]Will be assessed using CTCAE version 4.0. Descriptive statistics will be computed. Safety will be compared in two separate analyses among different treatment regimens: treatment group 1 vs. treatment group 2, treatment group 2 vs. treatment group 3, and among different SBRT targets liver vs lung: treatment group 2 vs. treatment group 3.
- Incidence of adverse events of nivolumab with BMS-986156 and SBRT targeting lung lesions [ Time Frame: Up to 1 year ]Will be assessed using CTCAE version 4.0. Descriptive statistics will be computed. Safety will be compared in two separate analyses among different treatment regimens: treatment group 1 vs. treatment group 2, treatment group 2 vs. treatment group 3, and among different SBRT targets liver vs lung: treatment group 2 vs. treatment group 3.
Secondary Outcome Measures :
- Treatment Success Defined by Immune-related Responses [ Time Frame: Up to 1 year ]Assessment of antitumor activity of ipilimumab & nivolumab with BMS-986156 & SBRT for 1-4 lung lesions in both SBRT treated lesion and non-irradiate tumors where treatment success defined as immune-related complete response (irCR) or immune-related partial response (irPR) or immune-related stable disease (irSD), assessed using immune-related response criteria (irRC) (e.g. the best response obtained by a patient).irCR, complete disappearance all lesions (whether measurable or not, no new lesions) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irPR, decrease in tumor burden ≥50% relative to baseline confirmed by consecutive assessment at least 4 week after first documentation; irPD, increase in tumor burden ≥25% relative to nadir (minimum recorded tumor burden) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irSD, not irCR or irPR, in absence of irPD, does not require repeat confirmation.
- Treatment Success Defined by Immune-related Responses [ Time Frame: Up to 1 year ]Assessment of antitumor activity of ipilimumab with or without BMS-986156 as well as nivolumab with BMS-986156 with SBRT treatment for 1-4 liver lesions in both the SBRT treated lesion and non irradiate tumors where treatment success defined as irCR or irPR or irSD, assessed using irRC (e.g. the best response obtained by a patient).irCR, complete disappearance all lesions (whether measurable or not, no new lesions) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irPR, decrease in tumor burden ≥50% relative to baseline confirmed by consecutive assessment at least 4 week after first documentation; irPD, increase in tumor burden ≥25% relative to nadir (minimum recorded tumor burden) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irSD, not irCR or irPR, in absence of irPD, does not require repeat confirmation. Clinical benefit established as having irSD for up to 6 months for irSD.
- Response of non-irradiated tumors [ Time Frame: Up to 1 year ]Comparison of response of non-irradiated tumors between BMS-986156 with ipilimumab vs BMS-986156 with nivolumab done using irRc (e.g. the best response obtained by a patient).irRc efined as irCR, complete disappearance all lesions (whether measurable or not, no new lesions) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irPR, decrease in tumor burden ≥50% relative to baseline confirmed by consecutive assessment at least 4 week after first documentation; irPD, increase in tumor burden ≥25% relative to nadir (minimum recorded tumor burden) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; ; irSD, not irCR or irPR, in absence of irPD, does not require repeat confirmation. Clinical benefit established as having irSD for up to 6 months for irSD.Comparisons between groups will be assessed with regard to the irRC outcomes.
- Predictive potential value of tumor-associated and systemic immune biomarkers [ Time Frame: Up to 1 year ]For the predictive potential value of tumor-associated and systemic immune biomarkers, comparisons will be performed between group 2 (Ipilimumab plus BMS-986156 with SBRT) and group 3 (Nivolumab plus BMS-986156 with SBRT) per treatment site (liver or lung). Potential values may be summarized as qualitative or descriptive lists.
- Adverse events will be evaluated using skeletal mass, neutrophil, neutrophil to lymphocyte ratio, and tumor bulk. [ Time Frame: Up to 1 year ]It will be evaluated whether skeletal mass, neutrophil, neutrophil to lymphocyte ratio, and tumor bulk are correlated with clinical outcomes and adverse events.Correlation may be summarized as qualitative or descriptive list of item's possible association to clinical outcome and/or adverse event.
- Treatment response [ Time Frame: Up to 1 year ]It will be evaluated whether tumor kinetics in combination with clinical correlates can help determine treatment response. The radiological response and clinical data will be analyzed using mathematical and statistical models to identify prognostic groups.
- Tumor mutational burden [ Time Frame: Up to 1 year ]Will be correlated with improved clinical outcomes and response criteria.
- Progression of non-irradiated tumors [ Time Frame: Up to 1 year ]Comparison of progression of non-irradiated tumors between BMS-986156 with ipilimumab vs BMS-986156 with nivolumab done using irRc where treatment success defined as Response Evaluation Criteria in solid Tumors (RECIST) version 1.1: Complete Response (CR): Disappearance all target lesions; Partial Response (PR): At least 30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): At least 20% increase in sum LD target lesions, reference smallest sum LD recorded since treatment started or appearance 1/> new lesions; Stable Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for PD, reference smallest sum LD since treatment started
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients must have histological confirmation of solid metastatic cancer with at least one metastatic or primary lesion in the liver or lung/chest, except for group 1.
- Patients who have completed prior systemic anti-cancer therapies, an interval of 5 drug half-lives or 4-weeks whichever is shorter, is required, prior to enrollment on study. Note: patients with anaplastic thyroid will be waived from this inclusion criteria given the rapid trajectory of their disease
- All patients must have at least one metastatic or primary lesion within the lung/chest or liver located in an anatomical location amenable to SBRT treatment with 50 Gy in 4 fractions or with 60 Gy in 10 fractions, except for group 1.
- Repeat radiation in fields previously radiated will be allowed at the discretion of the treating physician
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky > 60%)
- Total bilirubin =< 2.0 mg/dL (does NOT apply to patients with Gilbert's syndrome) (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x institutional upper limit of normal (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
- White blood count (WBC) >= 2500/uL (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
- Absolute neutrophil count (ANC) >= 1000/uL (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
- Platelets >= 75K (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
- Hemoglobin >= 9 g/dL (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
- Creatinine =< 2.0 x upper limit of normal (ULN) (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
- Patients must be willing and able to review, understand, and provide written consent before starting therapy
- Patients with brain metastasis will be included as long as they are free of neurologic symptoms related to metastatic brain lesions and who do not require or receive systemic corticosteroid therapy, > 10 mg/day in the 14 days prior to beginning the trial (=< 10 mg steroid, e.g.: prednisone, is allowed). Patients with stable brain metastases (clinically and radiographically) for >= 4 weeks to enroll on the protocol.
- Patients that have previously progressed on immunotherapy such as ipilimumab, anti-PD-I, anti-PDL-1 or talimogene laherparepvec (T-VEC) will be eligible.
Exclusion Criteria:
- Serious autoimmune disease at the discretion of the treating attending: patients with a history of active serious inflammatory bowel disease (including Crohn's disease and ulcerative colitis) and autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus or autoimmune vasculitis (e.g., Wegener's granulomatosis) are excluded from this study
- Active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, abdominal carcinomatosis or other known risk factors for bowel perforation
- Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events (AEs): e.g. a condition associated with frequent diarrhea or chronic skin conditions, recent surgery or colonic biopsy from which the patient has not recovered, or partial endocrine organ deficiencies
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, history of congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Known active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C that has not been documented to be stable
- Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to one month prior to or after any dose of ipilimumab)
- Concomitant therapy with any of the following: IL-2, interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroids while receiving ipilimumab (as long as steroid replacement is significantly greater than what is required for physiologic replacement, i.e. in hypothyroidism)
- Pregnant women are excluded from this study. Women of child-bearing potential (WOCBP) must have a pregnancy test every 4 weeks and WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of immunotherapy drugs (ipilimumab/nivolumab/BMS-986156), during the course of the treatment and 160 days AFTER the last dose of study drug you should not get pregnant or breast feed. In the case of male participants, during the course of treatment and 220 days AFTER the last dose of immunotherapy you should not father a child (condom use is mandatory, even if vasectomized) or donate sperm. For contraception guidelines please see protocol
- History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician
- Prior allogeneic stem cell transplantation
- Patients who were intolerant to previous immuno-oncology (IO) drugs should be excluded
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04021043
Locations
| United States, Texas | |
| M D Anderson Cancer Center | |
| Houston, Texas, United States, 77030 | |
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
| Principal Investigator: | James Welsh | M.D. Anderson Cancer Center |
Additional Information:
| Responsible Party: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT04021043 |
| Other Study ID Numbers: |
2018-0419 NCI-2019-00405 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 2018-0419 ( Other Identifier: M D Anderson Cancer Center ) |
| First Posted: | July 16, 2019 Key Record Dates |
| Last Update Posted: | February 16, 2023 |
| Last Verified: | February 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Carcinoma Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Antineoplastic Agents, Immunological Nivolumab Ipilimumab Antibodies |
Immunoglobulins Antibodies, Monoclonal Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |